Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Blood (2025) 146 (Supplement 1): 2290.

https://doi.org/10.1182/blood-2025-2290

Published: 2025

Journal Articles

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Blood (2025) 146 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2025-3949

Published: 2025

Journal Articles

Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.

Adolfo Aleman, Rudra Prasad Dutta, Oliver Van Oekelen, David Melnekoff, Tarek Mouhieddine, Leah Grossman, Sidorela Reci, Shriya Desai, Patrick Brunner, Alessandro Lagana, Sundar Jagannath, Joshua Brody, Samir Parekh

Blood (2025) 146 (Supplement 1): 3946.

https://doi.org/10.1182/blood-2025-3946

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

Maria Victoria del Rosal, Saoirse Bodnar, Tehilla Brander, Madeline Katz, Whilhelm Genthe, Kenan Onel, Sundar Jagannath, Alessandro Lagana, Samir Parekh, Santiago Thibaud

Blood (2025) 146 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2025-2151

Published: 2025

Journal Articles

Epigenetic targeting of SETD8 in multiple myeloma

Rudra Prasad Dutta, He Chen, Yue Zhong, Anqi Ma, Adolfo Aleman, Alison Park, Shriya Desai, Sidorela Reci, Ivan Odak, Ioanna Tsialta, Kedwin Ventura, H. Ümit Kaniskan, Alessandro Lagana, Jian Jin, Samir Parekh

Blood (2025) 146 (Supplement 1): 3310.

https://doi.org/10.1182/blood-2025-3310

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Blood (2025) 146 (Supplement 1): 916.

https://doi.org/10.1182/blood-2025-916

Published: 2025

Journal Articles

Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies

Mujahid Quidwai, Santiago Thibaud, Sundar Jagannath, Samir Parekh, Alessandro Lagana

Blood (2025) 146 (Supplement 1): 2646.

https://doi.org/10.1182/blood-2025-2646

Published: 2025

Journal Articles

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Blood (2025) 146 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2025-3996

Published: 2025

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Junia Vieira, Alison S Park, Edgar Gonzalez-Kozlova, David Melnekoff, Sherry Bhalla, Chaitanya Acharya, Mark Hamilton, George Mulligan, Immune Atlas Network, Hearn Jay Cho, Li Ding, Sacha Gnjatic, Ioannis S Vlachos, Manoj Bhasin, Sundar Jagannath, Samir Parekh, Alessandro Lagana

Blood (2024) 144 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2024-208677

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Saoirse Bodnar, Tehilla Brander, Zachary M Avigan, William Genthe, David Melnekoff, Alessandro Lagana, Jane Houldsworth, Shambavi Richard, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Hearn Jay Cho, Kenan Onel, Sundar Jagannath, Manisha Balwani, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2024-212204

Published: 2024

Journal Articles

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Blood (2024) 144 (Supplement 1): 357.

https://doi.org/10.1182/blood-2024-204929

Published: 2024

Journal Articles

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Adolfo Aleman, Rongbao Zhao, Leah Grossman, Rahul Sanawar, Srinivas Aluri, Mani Mohindru, Rudra Prasad Dutta, Sidorela Reci, Junia Vieira, David Melnekoff, Alessandro Lagana, Shriya Desai, Sundar Jagannath, Amit Verma, Samir Parekh

Blood (2024) 144 (Supplement 1): 589.

https://doi.org/10.1182/blood-2024-201194

Published: 2024

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Selma Bekri, Simone Katz, Geoffrey Kelly, Travis Dawson, Darwin D'Souza, Michael Mason, Alexandre Alloy, Shameek Biswas, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, Sundar Jagannath, Alessandro Lagana, Hearn Jay Cho

Blood (2023) 142 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2023-189882

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

Epigenetic targeting of SETD8 in multiple myeloma

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only